A phase II trial of induction NAB-paclitaxel and cisplatin...
https://www.researchgate.net/publication/319837787...
Request PDF | A phase II trial of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma | Objectives...

Secondary resectability in locally advanced pancreatic...
https://www.researchgate.net/publication/330065869...
Home; Endocrine Gland Neoplasms; Neoplasms

154361-50-9 | MFCD00930626 | 5'-Deoxy-5-fluoro-N ...
https://www.aablocks.com/prod/154361-50-9 →
Title: Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with Capeptabine for locally advanced pancreatic cancer. Journal. Cancer chemotherapy and pharmacology 2012091
Offer Count: 4 Price Range: $5 - $35

www.science.gov
https://www.science.gov/topicpages/a/advanced+inoperable+squamous.html →

Search result for 'advanced dermal fillers'
https://www.dovepress.com/search_results.php... →

clinicaltrials.gov
https://clinicaltrials.gov/ct2/results?displayxml=true&count=1000&start=64001
Recruiting Advanced Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage...
Induction chemotherapy with albumin-bound paclitaxel plus lobap ...
Jul 01, 2021. Although the FP regimen is the standard regimen for CRT for esophageal cancer, paclitaxel plus platinum agent has also been used as one of the main options for nearly a decade. In 2014, Tang et al. treated patients with locally advanced ESCC with 3-week schedule paclitaxel and cisplatin-based definitive CRT. The results showed that the ...

Author: J. Zeng, X. Cai, L. Chong, Y. Chen, X. ...
Publish Year: 2021
Males: 72

multi-institutional randomized phase III study comparing ...
https://academic.oup.com/rct/article/51/5/636/6174321

Author: Ryo Shimoyama, Shota Omoni, Shig...
Publish Year: 2021

Phase II study of neoadjuvant therapy with nab-paclitaxel ...
https://europepmc.org/article/MED/27244882
Aug 01, 2016. Background We carried out a phase II study to evaluate the efficiency and safety of the combination of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and cisplatin as preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma (ESCC). Results: From Oct 2011 to Dec 2012, 35 patients were enrolled and received neoadjuvant chemotherapy.

Cited by: 2
Author: Yun Fan, Youhua Jiang, Xinning Zhou, Qi...
Publish Year: 2016

The antitumor effect of lobaplatin against Ishikawa ...
Jun 01, 2019. The CCK-8 assay was used to evaluate anti-proliferative effect of lobaplatin on Ishikawa cells. After the treatment of lobaplatin for 48 h, the proliferation of Ishikawa cells was markedly attenuated and represented a dose-dependent manner (Fig. 1A). the inhibition rates were 34.73 ± 0.79% and 56.3 ± 0.63% respectively at 2μg and 4μg/mL dosage, which led to a significant inhibition of...
Clinical Trials Study
Induction chemotherapy with albumin-bound paclitaxel plus platin followed by concurrent radiochemotherapy for locally advanced esophageal cancer

Yan MH et al. Induction chemotherapy for locally advanced esophageal cancer

Mao-Hui Yan, Feng Liu, Bo-Lin Qu, Bo-Ning Cui, Wei Yu, Xue-Qin Dai

Abstract
BACKGROUND
Phase II study of neoadjuvant therapy with nab-paclitaxel ...
https://europepmc.org/article/MED/27244882
Aug 01, 2016 - Background We carried out a phase II study to evaluate the efficiency and safety of the combination of nanoparticle albumin bound-paclitaxel (nab-paclitaxel) and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma (ESCC). Results: From Oct 2011 to Dec 2012, 35 patients were enrolled and received neoadjuvant chemotherapy.
Cited by: 2 Author: Yun Fan, Youhua Jiang, Xinming Zhou, Qi... Publish Year: 2016

Liposome-paclitaxel and carboplatin combination ...
Jul 01, 2021 - Although the FP regimen is the standard regimen for CCRT for esophageal cancer, paclitaxel plus platinum agent has also been used as one of the main options for nearly a decade. In 2014, Tang et al. treated patients with locally advanced ESCC with 3-week schedule paclitaxel and cisplatin-based definitive CCRT. The results showed that the ...
Author: J. Zeng, X. Cui, L. Cheng, Y. Chen, X. ... Publish Year: 2021

multi-institutional randomized phase III study comparing ...
https://academic.jco.org/article/51/5/636/6174321
Mar 17, 2021 - A multi-institutional randomized phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin as regimens for concurrent chemoradiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Japan Clinical Oncology Group Study JCOG1914
Author: Ryo Shimoyama, Shota Omori, Shog... Publish Year: 2021

The antitumor effect of lobaplatin against Ishikawa ...
Jun 01, 2019 - The CCK-8 assay was used to evaluate anti-proliferative effect of lobaplatin on Ishikawa cells. After the treatment of lobaplatin for 48 h, the proliferation of Ishikawa cells was markedly attenuated and represented a dose-dependent manner (Fig. 1A); the inhibition rates were 34.73 ± 0.79% and 66.3 ± 0.63% respectively at 2ug and 4ug/mL dosage, which led to a significant inhibition of ...
Author: Jingchao He, Haijun Zhang Publish Year: 2019